Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.0052 reality
.006 without news
Move over King & co, there’s a new set of bandits in town.
They are definitely searching near to nonexistent diseases to try to get their contracts for development. Such a farce. Out with the old scum in with the new.
What about contracts that involve real dollars instead of contracts for near to non-existent Diseases. Another scam is brewing here.
Was all one big sham by King Swartz Carlton Lytle etc. hopefully they face jail time one day.
We go from one of the most read boards to a few posts a day....
Possibly who knows
Definitely fired. Let the public think he resigned.
Moving where??
To the moon
You can’t even make this up! Pretty amazing. Where is the SEC?
If this isn’t called insider trading then I must not know what it is. Unbelievable. Crooks. Thieves. Go directly to jail.
LMAO!! Crooks!!
Yup. Fraud at its finest.
Avid releases PRs of secondary offering on 2/14, and this is the most recent Ronin activity:
Common Stock:
· On February 9, 2018, Ronin Trading, LLC sold 120,997 shares at a price of $3.2061 per share.
· On February 12, 2018, Ronin Trading, LLC sold 29,003 shares at a price of $3.1884 per share.
· On February 15, 2018, Ronin Trading, LLC purchased 1,350,000 shares at a price of $2.2500 per share.
Doesn’t look too legit to me...
Anyone else?
No other sales prior...
Days before they sell?? Hmmmm
And I am sure we will see a filing from Tappan... Dart must have also participated.
There is no way Stafford didn’t know that a secondary was coming....
Who knows. Soon to be dumped on the open market
Hopefully we never hear from him again ??
Ok. Not mine
What was yours
Something like sorry for those who sold. Announcement coming out
And you?
I did from someone that I cannot remember
Ya like from who
Most likely sick and tired of giving biz this fraud company and prior bod
Who knows. They could be hiding orders in their back pocket. It wouldn’t surprise me.
All I can say at least it’s not an ATM cuz we’ve already been shown that porn move too many times. Couldn’t help myself.
Are they raising $125MM now? Does it say that? They can but most likely not.
That’s most likely in every public offering
At least it’s not an ATM but a secondary.
I am in the USA.
Bastards should be tarred and feathered then a good stoning.
Unbelievable. They had the balls to release it after hours on Wednesday instead of Friday.
Agreed. Very shady.
Complete sham. Total bs
Something isn’t kosher here
We could have made a much better deal than these fools.
Agreed. Total BS
Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including...
Source: GlobeNewswire Inc.
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for Avid’s phosphatidylserine (PS)-targeting program including bavituximab. Bavituximab is an investigational immune-modulatory monoclonal antibody that targets PS, a phospholipid that inhibits the ability of immune cells to recognize and fight tumors. In addition to bavituximab, the deal includes Avid’s other PS-targeting antibodies, including betabodies, as well as certain other assets and licenses useful and/or necessary for the potential commercialization of bavituximab.
Under terms of the agreement, Avid will receive an aggregate of $8 million in upfront payments from Oncologie paid over a period of six months from the execution date of the agreement and will be eligible to receive up to $95 million in development, regulatory and commercialization milestones. Oncologie will be responsible for all future research, development and commercialization of bavituximab, and related intellectual property costs, with Avid receiving royalties on net sales that are upward tiering into the mid-teens. As part of the deal, Oncologie will also enter into an agreement with Avid for future contract development and manufacturing activities in support of bavituximab. Roth Capital Partners acted as financial advisor to Avid in this transaction, rendering a Fairness Opinion to its board of directors.
“Partnering our PS-targeting program including bavituximab with a biopharmaceutical company focused on therapeutics in oncology has long been a key corporate objective and we have engaged in discussions with a broad range of potential collaborators throughout the course of the development program. Oncologie is a company with a deep understanding of cancer biomarkers that might be particularly relevant to bavituximab and we believe they have the resources and expertise to maximize the potential of the program,” said Roger J. Lias, Ph.D., president and chief executive officer of Avid. “Importantly, this deal marks the completion of our transition to a dedicated CDMO, while providing additional capital, both upfront and potentially downstream, to support our CDMO business.”
“We are pleased to add bavituximab as our new lead development program through this agreement with Avid,” said Laura E. Benjamin, Ph.D., chief executive officer of Oncologie. “We believe that PS targeting possesses significant promise in the treatment of cancer and look forward to highlighting the therapeutic potential of the approach through innovative clinical trials. To this end, we intend to continue ongoing collaborations with the current investigators who are overseeing investigator-initiated trials, as well as NCCN-sponsored studies, designed to evaluate the immune modulating potential of bavituximab.”
Bavituximab is believed to reverse PS-mediated immunosuppression by blocking the engagement of PS with its receptors, as well as by sending an alternate immune activating signal. PS-targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in multiple signs of immune activation and anti-tumor immune responses. This mechanism may play an important role in allowing other cancer therapies to more effectively attack tumors by reversing the immunosuppression that limits the impact of those treatments. Importantly, bavituximab has also demonstrated a favorable safety and tolerability profile across several clinical trials conducted to date, which may offer the compound a key advantage as the evolving cancer treatment landscape continues to shift to a combination therapy approach. The ability to be added to a range of other cancer therapies without causing added safety concerns may position bavituximab favorably as a component of combination treatments.
About Oncologie, Inc.
Oncologie is an oncology therapeutics company committed to delivering improved outcomes for cancer patients by leveraging innovative compounds and biomarker-driven clinical development. The current pipeline is focused on mid-stage clinical programs that modify the tumor microenvironment. Headquartered in Boston, Massachusetts with operations also in Shanghai, China, Oncologie is working with global partners to acquire and develop innovative drugs for cancer patients around the world. www.oncologie.international
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Avid Bioservices’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk the company may not receive any of the up to $95 million in development, regulatory and commercial milestones under the agreement with Oncologie, nor any future royalty payments. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2017 as well as any updates to these risk factors filed from time to time in the company's other filings with the Securities and Exchange Commission. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Avid Bioservices, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Laura E. Benjamin
Oncologie, Inc.
info@oncologie.international
Primary Logo
And still waiting for your reply